The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on their Breast Oncology team. With an enthusiastic passion for medical affairs, the new Senior Medical Advisor has hit the ground running as she joins the leadership team of Lilly’s Verzenio (Abemaciclib) enterprise. The Chase Group is proud to partner with Eli Lilly and connect them with high caliber talent that will create medicines to make life better for people around the world
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on their Breast Oncology team. With an enthusiastic passion for medical affairs, the new Senior Medical Advisor has hit the ground running as she joins the leadership team of Lilly’s Verzenio (Abemaciclib) enterprise. The Chase Group is proud to partner with Eli Lilly and connect them with high caliber talent that will create medicines to make life better for people around the world- Categories: Life Sciences, Pharmaceutical
Aeglea Biotherapeutics Secures Another Executive for their Clinical Development Leadership Team
To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program…
Eli Lilly Cyramza® Team Grows Through Continued Partnership with Chase
Utilizing their knowledge and years of experience recruiting in the life sciences industry, The Chase Group has successfully secured a new Global Senior Medical Advisor,…
A New Era Begins with Head of Pathology Placement at Genmab
Dr. Suzana Couto joins Genmab Pharmaceuticals as Head of Pathology, leading the pathology teams located in Utrecht, Netherlands, and Princeton, New Jersey. This international biotechnology…-
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on… -
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in… -
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate…